ArticleBMC complementary medicine and therapies2025
Pharmacological assessment of the extract and a novel compound of Bacillus velezensis DM derived from the rhizosphere of Datura metel L. with microbial molecular screening.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Endophytic fungus Muyocopron dipterocarpi isolated from Catharanthus roseus as a novel producer of ajmalicine and other metabolites: insights from HPLC and LC-HRMS analysis.Antonie van Leeuwenhoek · 2026Article
- Metabolite profiling of Bacillus velezensis DM extract linked to the rhizosphere of Datura metel L. and dermatoprotective potential of an isolated glycoglycerolipid.Microbial cell factories · 2026Article
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRhizosphere bacteria were considered a prospective reservoir of bioactive compounds with significant pharmacological efficacy.
methodsFrom the rhizosphere of Datura metel L., Bacillus velezensis DM was isolated and characterized using 16 S rRNA. PCR screening and sequencing were conducted to identify genes related to bioactive metabolite production. The extraction of secondary metabolites from the bacterial strain was performed via a fermentation process. The ethyl acetate extract of the propagated strain was subjected to fractionation and purification through various chromatographic techniques. The characterization of the isolated compounds was accomplished using different spectroscopic methods, such as 1D and 2D-NMR. An MTT test was conducted to assess the cytotoxic activity of bacterial extract on MCF-7, HepG-2, and HCT-116 cells. Furthermore, its pure compound (1) was tested for its cytotoxicity on HCT-116 and a normal cell (THLE2) to test its safety for normal cells. Apoptosis was identified through flow cytometry on HCT-116 cells after double-staining with PI and annexin V-FITC. The antioxidant action of bacterial extract was assessed through DPPH and ABTS assays. Furthermore, anti-inflammatory evaluations were carried out employing lipoxygenase (5-LOX) and cyclooxygenase (COX-2) inhibition.
resultsThe NCBI GenBank database has effectively incorporated the 16 S rRNA gene sequence of Bacillus velezensis DM under the accession number OR364492. Polyketide synthase and two lipopeptide genes for surfactin and iturin A were effectively detected by PCR, and their sequences were included in the Genbank database. A novel compound, 5,6-di(methylamino)hex-5-ene-1,2,3-triol (1), was successfully separated from the strain. Bacterial extract demonstrated significant cytotoxic activity against the evaluated cancer cells, exhibiting the most pronounced effect on HCT-116 cells. Compound (1) showed promising cytotoxic potential against HCT-116 cells with a higher selectivity index (2.5) towards cancer cells in comparison to Doxorubicin (1.49). Apoptosis assay showed that bacterial extract caused apoptosis about 14 folds compared to the control HCT-116 cells. Furthermore, it showed a potent anti-inflammatory outcome (IC
conclusionThis study revealed the possible pharmacological effects of secondary metabolites generated by Bacillus velezensis DM, making it a valuable resource for isolating bioactive compounds with potential therapeutic and biomedical uses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.